H.C. Wainwright Sticks to Its Buy Rating for Xenetic Biosciences (XBIO)


In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Xenetic Biosciences (XBIO), with a price target of $5.00. The company’s shares closed last Tuesday at $2.51.

According to TipRanks.com, Pantginis is a top 25 analyst with an average return of 50.1% and a 69.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Catabasis Pharmaceuticals, and Lineage Cell Therapeutics.

Xenetic Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $5.85 and a one-year low of $0.44. Currently, Xenetic Biosciences has an average volume of 634.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Xenetic Biosciences, Inc. is a biopharmaceutical company, which focuses on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. The XCART has the potential to fuel a robust pipeline of therapeutic assets targeting oncology indications. Additionally, Xenetic is leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. The PolyXen has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. Xenetic Biosciences was founded on and is headquartered in Framingham, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts